HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Acker, M. R. Articles by Burrell, S. C. Search for Related Content PubMed PubMed Citation Articles by Acker, M. R. Articles by Burrell, S. C.

Utility of ¹⁸F-FDG PET in Evaluating Cancers of Lung^*

Nuclear Medicine Division, Department of Diagnostic Imaging, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

ABSTRACT

PET has seen rapid progression in recent years, with applications in oncology leading the way. The glucose analog ¹⁸F-FDG is the most commonly used PET radiopharmaceutical and has been shown to accumulate avidly in several different neoplasms, including cancers of the lung. The following discussion will review the physiologic basis for the uptake of ¹⁸F-FDG in lung neoplasms and demonstrate the utility of ¹⁸F-FDG PET in lung cancer. A brief review of other PET radiopharmaceuticals in lung cancer imaging, and dual-modality PET/CT scanners, will be presented. Upon completion of this article, the reader should be able to describe the pharmacokinetics of ¹⁸F-FDG and discuss the efficacy of ¹⁸F-FDG PET scans in the evaluation of solitary pulmonary nodules, disease staging, and monitoring response to therapy. Additionally, the reader should be able to compare ¹⁸F-FDG PET with conventional anatomic imaging and describe some of the technical challenges of PET/CT fusion imaging.

Key Words: ¹⁸F-FDG PET; lung cancer